Another phase III clinical trial of Gemstone-301 analyzed patients with unresectable stage III NSCLC who do not have disease progression after concurrent/sequential radiotherapy and chemotherapy, which is the only study for self-produced anti-PD-L1 inhibitor in China. Here, CD274 is linked to non-small cell lung carcinoma.